Email Chinese

I-Mab Biopharma signs licensing agreement for HyLeukin with Genexine

Genexine to receive an upfront payment and entitled to tiered, single-digit royalties on net sales of HyLeukin plus milestone payments from I-Mab Biopharma (I-Mab)....


I-Mab Biopharma and MorphoSys Partnership on Cancer Investigational Medicine

I-Mab and MorphoSys AG announced today that they have entered into an exclusive regional licensing agreement to develop and commercialize MOR202 in China, Taiwan, Hong Kong and Macao....





Official Website Online!

With all our efforts, Third Venture Biopharma's official website (in Chinese) was officially in public test phase on 21 March 2017. We hope that we can serve for our clients in a more prudent and professional manner....


Third Venture Biopharma and Tasgen Merge to form I-Mab, Raises $150m in Series B Financing

March 21st, 2017, Tianjin, China – Third Venture Biopharma, a company focusing on the discovery and development of the innovative biologics, and Tasgen Biotech, a clinical stage biologics development company focused on half-life extension bio-betters, announced today a definitive merger agreement to create a leading innovative biologics platform in China....


Third Venture Biopharma built strategic partnership with Ferring Pharmaceuticals

On 19 December 2016, Third Venture Biopharma built strategic partnership with Ferring Pharmaceuticals, under which, Third Venture Biopharma was granted the exclusive rights to develop and commercialize Olamkicept (an autoimmune drug of Ferring Pharmaceuticals) for autoimmune indications in Asia....

Home Previous Next End 1/1page  6 10/page To:

Address: Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, China, 201210    Tel:86-21-6057 8000     Email:marcom@i-mabbiopharma.com